Performance of the SF-36, SF-12, and RAND-36 Summary Scales in a Multiple Sclerosis Population
- 1 October 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Medical Care
- Vol. 38 (10) , 1022-1028
- https://doi.org/10.1097/00005650-200010000-00006
Abstract
Multiple sclerosis (MS) patients accumulate both physical and mental health problems along with disease progression. Valid and sensitive outcome measures are important to measure disease effects and the effect of treatment. The objective of this study was to test the performance of the physical and mental summary scales of SF-36, SF-12, and RAND-36. The scales were evaluated by comparing the scores of a cohort of 194 MS patients with general population data and using the Expanded Disability Status Scale (EDSS) and the Incapacity Status Scale–mental as criterion variables for physical functioning and mental health. All 3 physical summary scales were markedly reduced and correlated highly with the EDSS. The SF-36 mental summary score was only slightly reduced among MS patients (0.2 SD) compared with the general population, despite significantly reduced scores on all 4 health scales being most related to mental health and despite a high prevalence of mental health problems. This results from the poor physical functioning (mean scale score, 2.3 SD below the general population) and the orthogonal factor rotation used to derive independent measures of physical and mental health. Similar results were found for the SF-12. The nonorthogonal RAND-36 physical and mental summary scores were both markedly reduced. This is more compatible with the disease progression in MS and the results of the other measures of physical and mental health used in the study. The SF-36 and SF-12 mental health summary scales appear to overestimate mental health in people with MS.Keywords
This publication has 21 references indexed in Scilit:
- Quality of life in multiple sclerosisNeurology, 1999
- Development of a multiple sclerosis functional composite as a clinical trial outcome measureBrain, 1999
- Type I interferons and the quality of life of multiple sclerosis patients. Results from a clinical trial on interferon alfa-2aMultiple Sclerosis Journal, 1999
- SF-36 Summary ScoresMedical Care, 1998
- Measurement of Health-Related Quality of Life in Multiple Sclerosis PatientsCanadian Journal of Neurological Sciences, 1996
- Outcomes assessment in multiple sclerosis clinical trials: a critical analysisMultiple Sclerosis Journal, 1995
- What Information Do Consumers Want and How Will They Use It?Medical Care, 1995
- Survival of patients with multiple sclerosis in DenmarkNeurology, 1994
- Prognostic factors for life expectancy in multiple sclerosis analysed byJournal of Clinical Epidemiology, 1988
- Rating neurologic impairment in multiple sclerosisNeurology, 1983